CTNNB1 and neoplasm: By 10.5-weeks, LNP-CTRL mice were all moribund with α-PD1 alone suggesting no impact on tumor burden, whereas the combination of LNP-CTNNB1 + α-PD1 resulted in enhanced efficacy with absence of any NR compared to LNP-CTNNB1 + IgG treated animals (Fig. 7f, g).